Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment of Breast Cancer: ctDNA-Guided Personalized Therapy

NCT07366112 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07366112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07366112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment of Breast Cancer: ctDNA-Guided Personalized Therapy
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 20, 2026
Completion date
December 31, 2029
Enrollment
158 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ctdna monitoring, early-stage breast cancer, her2-negative breast cancer, high-risk breast cancer, hormone receptor-positive breast cancer